Cytosolic sulfotransferase 1A1 regulates HIV-1 minus-strand DNA elongation in primary human monocyte-derived macrophages by Justine Swann et al.
RESEARCH Open Access
Cytosolic sulfotransferase 1A1 regulates
HIV-1 minus-strand DNA elongation in
primary human monocyte-derived
macrophages
Justine Swann1,2, Jeff Murry1,3 and John A. T. Young1,4*
Abstract
Background: The cellular sulfonation pathway modulates key steps of virus replication. This pathway comprises
two main families of sulfonate-conjugating enzymes: Golgi sulfotransferases, which sulfonate proteins, glycoproteins,
glycolipids and proteoglycans; and cytosolic sulfotransferases (SULTs), which sulfonate various small molecules
including hormones, neurotransmitters, and xenobiotics. Sulfonation controls the functions of numerous cellular factors
such as those involved in cell-cell interactions, cell signaling, and small molecule detoxification. We previously showed
that the cellular sulfonation pathway regulates HIV-1 gene expression and reactivation from latency. Here we show that
a specific cellular sulfotransferase can regulate HIV-1 replication in primary human monocyte-derived macrophages
(MDMs) by yet another mechanism, namely reverse transcription.
Methods: MDMs were derived from monocytes isolated from donor peripheral blood mononuclear cells (PBMCs)
obtained from the San Diego Blood Bank. After one week in vitro cell culture under macrophage-polarizing conditions,
MDMs were transfected with sulfotranserase-specific or control siRNAs and infected with HIV-1 or SIV constructs
expressing a luciferase reporter. Infection levels were subsequently monitored by luminescence. Western blotting was
used to assay siRNA knockdown and viral protein levels, and qPCR was used to measure viral RNA and DNA products.
Results: We demonstrate that the cytosolic sulfotransferase SULT1A1 is highly expressed in primary human MDMs, and
through siRNA knockdown experiments, we show that this enzyme promotes infection of MDMs by single cycle VSV-G
pseudotyped human HIV-1 and simian immunodeficiency virus vectors and by replication-competent HIV-1.
Quantitative PCR analysis revealed that SULT1A1 affects HIV-1 replication in MDMs by modulating the kinetics
of minus-strand DNA elongation during reverse transcription.
Conclusions: These studies have identified SULT1A1 as a cellular regulator of HIV-1 reverse transcription in
primary human MDMs. The normal substrates of this enzyme are small phenolic-like molecules, raising the
possibility that one or more of these substrates may be involved. Targeting SULT1A1 and/or its substrate(s)
may offer a novel host-directed strategy to improve HIV-1 therapeutics.
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Background
Host cellular machinery is exploited to facilitate all steps
of HIV-1 replication. A new paradigm in the treatment
of HIV-1 infection is to target these so-called host-
derived dependency factors, as exemplified by CCR5
coreceptor antagonists [1]. By contrast to the existing
classes of direct-acting antivirals (DAAs) that target viral
proteins, host-directed therapies may be less prone to
the development of viral drug resistance and offer the
potential for broader spectrum therapeutics [2, 3].
Therefore, there is currently a great deal of interest in
better understanding the roles played by cellular factors
and pathways during HIV-1 replication [4–8].
The cellular sulfonation pathway was first shown to play
a key role in regulating HIV-1 infection at the level of cellu-
lar entry [9–13]. Previously, we uncovered another role for
this pathway, demonstrating that it regulates retroviral tran-
scription [14]. In that study, a forward genetic screen impli-
cated two specific bi-functional 3′-phosphoadenosine-5′
phosphosulfate (PAPS) synthetase enzymes, PAPSS1 and
PAPSS2, as being important for retroviral replication [14].
These proteins catalyze two enzymatic steps to generate
PAPS, the high-energy sulfonate-donor used in all cellular
sulfonation reactions [15]. This specific effect was demon-
strated using two different inhibitors of the sulfonation
pathway: chlorate, a substrate analog of sulfate that blocks
PAPS formation; and guaiacol, a sulfotransferase substrate
mimic [14, 16]. In addition, we have recently shown that
treatment with these chemical inhibitors significantly
blocks HIV-1 reactivation from latency in a primary human
CD4+ T cell model and in established cell lines where la-
tency is maintained by diverse regulatory mechanisms [17].
The cellular sulfonation system consists of a family of
sulfotransferase enzymes that are responsible for sulfonate
transfer within the cell [18]. These proteins catalyze the
transfer of a sulfuryl group (SO3
−) from PAPS to a hydroxyl
or amino-group on an acceptor molecule. Sulfotrans-
ferases are organized into two main sub-families: the Golgi
and cytosolic sulfotransferases. The Golgi sulfotransferases
are membrane bound enzymes that sulfonate cell surface
proteins, carbohydrates, proteoglycans, and glycoproteins,
while the cytosolic sulfotransferases are cytoplasmic en-
zymes that sulfonate endogenous hormones, neurotrans-
mitters, and small metabolites as well as exogenous
xenobiotics (Fig. 1a). Cell surface sulfonation is necessary
during normal homeostatic processes such as lymphocyte
homing and cellular signaling [19–22]. Cytoplasmic sul-
fonation of metabolites by the cytosolic sulfotransferases
(SULTs) generally leads to their inactivation, detoxifica-
tion, and/or bioactivation [23–27]. Here we show that one
of these cytosolic sulfotransferases, SULT1A1, regulates
HIV-1 reverse transcription in MDMs, increasing our
knowledge of the roles played by cellular factors in regu-
lating HIV-1 reverse transcription.
Results
Human cytosolic sulfotransferase 1A1 is highly expressed
in primary human monocyte-derived macrophages
To determine if any of the 12 known cytosolic SULTs
might play a role in regulating HIV-1 infection, we first
compared their relative expression levels in the two
physiologically relevant cell types, primary human CD4+
T cells and primary monocytic cells. We employed the
publically available mRNA expression database Bio-GPS
[28]. This analysis revealed a strikingly high level of
SULT1A1 mRNA in CD14+ monocytes as compared to
other other cell types including CD4+ T cells (Additional
file 1: Figure S1). Although SULT1A1 was previously
found to be important in tissues such as the liver, brain,
kidney, and gastrointestinal tract, little or nothing is
known about its role in immune cells [29–31]. MDM-
selective expression was confirmed by immunoblot ana-
lysis of protein lysates obtained from primary human
CD4+ T cells and MDMs. In agreement with the mRNA
expression data, SULT1A1 was highly expressed in
MDMs. However, SULT1A1 protein expression was un-
detectable in resting or activated CD4+ T cells (Fig. 1b).
SULT1A1 knockdown decreases retroviral infection in
MDMs
To test if SULT1A1 plays a role during retroviral infec-
tion in MDMs, siRNA knockdown was used to reduce
the levels of this protein (Fig. 2a). Three distinct
SULT1A1-targeting siRNAs (#1–3) each reduced
SULT1A1 protein levels by 70–80 % at 96 h post-
transfection as compared to a control (scrambled se-
quence) siRNA (Fig. 2b, c middle panel). Each of the 3
SULT1A1 siRNAs also reduced the levels of infection
seen with a VSV-G-pseudotyped HIV-1 NL43 virus vec-
tor as judged by monitoring expression of the firefly lu-
ciferase reporter enzyme from the viral genome [32].
Knockdown of SULT1A1 expression with SULT1A1 siR-
NAs 1, 2, or 3 resulted in a decrease in HIV-1 reporter
gene expression by 50 % (p < 0.005), 76 % (p < 0.0005),
and 57 % (p < 0.005), respectively (Fig. 2c, left panel).
None of the siRNAs used significantly impacted cell via-
bility (Fig. 2c, right panel). The fact that all three
SULT1A1-directed siRNAs reduced viral gene expres-
sion following infection strongly argues against an indir-
ect off-target effect being responsible for this effect.
To test if SULT1A1 could also influence infection by
the related simian immunodeficiency virus, SULT1A1
siRNA-treated and control siRNA-treated MDMs were
infected with a VSV-G-pseudotyped SIVagm virus vector
encoding firefly luciferase (Fig. 2d) [33]. As for HIV-1,
RNAi-mediated knockdown of SULT1A1 directly corre-
lated with a significant reduction in expression of the
virus-encoded reporter enzyme, with an average of 85 %
inhibition (p < 0.0005) (Fig. 2d, left panel).
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To further validate the role of SULT1A1 during HIV-1
infection, we next investigated the impact of knocking
down expression of this protein on infection of MDMs
by replication-competent HIV-1. MDMs that were trans-
fected with control siRNA or with SULT1A1-siRNA#2
were challenged with the replication-competent CCR5-
tropic HIV-1 Env + JM1186 virus encoding Renilla lucif-
erase [34, 35] and luciferase expression was assayed
three days post infection (Fig. 3a). SULT1A1 knockdown
was associated with a significant inhibition of virus-
encoded luciferase expression in MDMs derived from
multiple donors without affecting cell viability (Fig. 3).
Transfection of these cells with SULT1A1 siRNA #2 re-
sulted in an average 72 % decrease in HIV-1 reporter ex-
pression compared to control (p < 0.0005) (Fig. 3, left
panel). Taken together, these results demonstrate that
SULT1A1 is important for efficient virus gene expression
following infection of MDMs with single cycle HIV-1
and SIV vectors and with replication-competent HIV-1.
SULT1A1 regulates HIV-1 reverse transcription
To determine the step in HIV-1 replication that is influ-
enced by SULT1A1, we monitored the effect of SULT1A1
siRNA #2 on early steps of virus replication at 24 h post-
infection. The VSV-G-pseudotyped HIV-1 vector was used
for these studies to avoid multiple cycles of virus infection
confounding the interpretation of the results. Quantitative
PCR methods were used to monitor viral DNA and RNA
products, focusing specifically upon spliced viral RNAs.
These RNAs are produced de novo in infected cells and
thus, are clearly distinguished from the large amounts of
input unspliced viral genomic RNA that are present in
these cells due to efficient virus uptake. Immunoblotting
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Fig. 1 SULT1A1 is highly expressed in primary human monocyte-derived macrophages (MDMs). a The cellular sulfonation pathway. The first
step of the cellular sulfonation pathway involves import through a sulfate transporter of a sulfate ion that is then used as a substrate by
either 3′-phosphoadenosine-5′phosphosulfate (PAPS) synthetase enzymes PAPSS1 or PAPSS2. These proteins catalyze two enzymatic steps
to generate PAPS, the high-energy universal sulfonate-donor from sulfate and two molcules of ATP. PAPS can be transported across the Golgi membrane
and used by the Golgi sulfotransferases to generate sulfonated proteins, glycoproteins, glycoproteins, glycolipids, and proteoglycans. Alternatively, PAPS
can be used by cytosolic sulfotransferases (SULTS) to sulfonate small molecules such as hormones, neurotransmitters, and xenobiotics. b Human CD4+ T
cells and CD14+ monocytes were isolated from donor PBMCs by magnetic bead isolation. Resting CD4+ T cells were lysed directly after separation, and
the remaining CD4+ T cells were activated using CD3/CD28 beads for three days. Monocytes were cultured for 7 days in the presence of 20 ng/ml M-CSF,
were lysed, subjected to gel electrophoresis, and immunoblotting was performed to detect SULT1A1 or the loading control Ku86 protein
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independent viral proteins (Vpu and Vif), that are pro-
duced from spliced HIV-1 mRNA transcripts.
These studies revealed that SULT1A1 had no effect
upon the levels of early reverse transcription products
(defined as those generated prior to minus-strand DNA
transfer) (Fig. 4a, left panel). By contrast, knockdown
of SULT1A1 was associated with a reduction (58 %,
p < 0.0005) in the levels of late reverse transcription
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Fig. 2 SULT1A1 knockdown is associated with decreased viral gene expression following infection of MDMs with VSV-G pseudotyped HIV-1 and
SIV vectors. a Schematic showing experimental timeline. Briefly, CD14+ monocytes were isolated from human donor PBMCs using positive selection
with magnetic beads. Monocytes were differentiated into MDMs and on day 7 were electroporated with siRNA and plated at 1.5 × 104 MDMs per well
in a 48 well plate. After 96 h, protein knockdown was confirmed by immunoblot and cells were infected with 100 μl (corresponding to
164 ng p24 HIV-1 and 234 ng p27 SIV viral vectors) of the indicated virus. Luciferase and cell viability measurements were determined at
24 h post-infection. b Representative immunoblot showing SULT1A1 knockdown 96 h post transfection with SULT1A1 siRNAs (1–3) and
AllStars Negative siRNA Control (ASN), Qiagen. SULT1A1 expression is compared to endogenous Ku86 used as a loading control. Results
from one representative donor are shown. SULT1A1 expression was generally decreased by 70–80 % with siRNA treatment compared to the control
ASN siRNA (as shown in Fig. 2c, middle panel). c HIV-1 luciferase reporter expression (left panel), SULT1A1 protein expression (middle panel), and cell
viability of MDMs (right panel) were measured 24 h after infection with the VSV-G pseudotyped NL43-Luc HIV-1 vector. Results shown are from 6
donors assayed twice. All values were compared to ASN control. d SIV-1 luciferase reporter expression (left panel), SULT1A1 protein expression (middle
panel), and cell viability (right panel) for MDMs 24 h post infection with VSV-G-pseudotyped SIVagm-Luc. Mean and SD shown, *** p< 0.0005 ** p< 0.005
* p< 0.05 one sample t test. Results shown are from 6 donors assayed twice. Samples with <60 % SULT1A1 knockdown and/or <65 % cell viability were
not used in the analysis. All values were compared to ASN control
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products (defined here as those generated subsequent
to minus-strand DNA transfer) (Fig. 4a, right panel).
Consistently, SULT1A1 knockdown in MDMs was as-
sociated with a 72 % reduction in levels of HIV-1
multiply spliced RNA (forward and reverse primers
span the first and second exons of Tat/Rev, respect-
ively (p < 0.0005) (Fig. 4b). Furthermore, SULT1A1
knockdown was also correlated with a 70 % reduction
in the levels of both the HIV-1 Vif and Vpu proteins
(p < 0.0005) (Fig. 4c-d). Taken together, these results
indicate that the predominant effect of SULT1A1 on
HIV-1 replication is at the level of viral DNA
synthesis.
SULT1A1 influences the kinetics of HIV-1 minus-strand
DNA elongation
In order to determine the specific stage of HIV-1 reverse
transcription that is influenced by SULT1A1, MDMs were
transfected with SULT1A1-specific or control siRNA prior
to infection with VSV-G pseudotyped NL43-Luc HIV-1
vector and DNA was isolated at different time points
post-infection (ranging from 8–24 h). The relative abun-
dance of different length reverse transcription products
was then measured using a series of oligonucleotide
primers that were used to amplify different regions of
HIV-1 DNA (labeled in order of appearance as follows:
ERT, U3-R, 2 KB, 4 KB, 8 KB, LRT (Fig. 5a).
Consistent with our previous result (Fig. 4), the abun-
dance of early reverse transcription products (ERT and
U3-R) was largely the same in both SULT1A1 siRNA
transfected and control transfected cell populations
(Fig. 5b all panels). By contrast, there was a marked re-
duction of DNA products longer than 2 kb in length at
8 h post-infection in cells deficient in SULT1A1 (Fig. 5b,
left panel). The defect in 2 kb products was less pro-
nounced at 16 h post-infection and was not evident at
24 h post-infection (Fig. 5b). Similarly the defect in the
level of 4 kb products was less pronounced at 24 h as
compared with 16 h post-infection. The defect seen in
the levels of longer 8 kb and LRT products was not
overcome in the 24-h time frame. Taken together, these
results show that SULT1A1 knockdown is associated
with a decreased progression of reverse transcription, a
result that is consistent with this enzyme playing an im-
portant role during the kinetics of viral minus strand
DNA elongation.
Discussion
This study demonstrates that the cellular sulfotransfer-
ase SULT1A1 regulates HIV-1 reverse transcription in
primary human monocyte-derived macrophages
(MDMs). We showed that SULT1A1 is highly expressed
in MDMs and that RNAi-mediated depletion of
SULT1A1 in these cells results in a significant reduction
in the kinetics of minus-strand DNA elongation during
HIV-1 reverse transcription.
The synthesis of HIV-1 proviral DNA from the viral
RNA genome is heavily regulated by cellular factors;
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Fig. 3 SULT1A1 knockdown is associated with decreased viral gene expression following infection of MDMs with a replication-competent HIV-1
vector. a The same method was used as in Fig. 2a, however 100 μl (corresponding to 66.3 ng p24) HIV-1 Env + JM1186-Rluc virus was added to
the cells at day 11 and luciferase and cell viability was assayed at 72 h post-infection. b HIV-1 luciferase reporter expression, SULT1A1 protein
expression, and cell viability of MDMs 24 h post infection with HIV-1 Env + JM1186-RLuc.. Mean and SD shown, *** p < 0.0005 ** p < 0.005 * p < 0.05
one sample t test. Results shown are from 6 donors assayed twice. Samples with <60 % SULT1A1 knockdown and/or <65 % cell viability were not used
in the analysis. All values were compared to ASN control
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however, only a small number of these factors have been
well characterized to date [36–39]. These proteins in-
clude SAMHD1, which blocks reverse transcription in
myeloid cells and resting CD4+ T cells by hydrolyzing
dNTPs and/or degrading viral RNA [40–43], and APO-
BEC3G, which deaminates cytidine to uridine resulting
in hypermutation during DNA synthesis [44, 45]. In
addition, other factors have been shown to affect the
kinetics of viral DNA synthesis [5]. Thus, the studies de-
scribed in this report extend our understanding of the
roles of cellular factors in regulating this key step of
retroviral replication. This novel role for SULT1A1 in
the regulation of retroviral reverse transcription also
adds to our growing knowledge about the diverse roles
that the sulfonation pathway plays in the retroviral life
cycle. For example, tyrosylprotein sulfotransferases 1
and 2 (TPST1 and TPST2) are Golgi sulfotransferases
that sulfonate N-terminal tyrosine residues of CCR5 and
enable efficient cellular entry of R5-tropic viruses [9, 10,
13]. It has also been demonstrated that HIV-1 binds to
sulfonated proteoglycans on cell surfaces [11, 12]. In
addition, we previously showed that PAPSS deficiency or
treatment of cells with the sulfonation pathway inhibi-
tors chlorate and guaiacol blocked HIV-1 de novo gene
expression from the viral LTR promoter, and more re-
cently we showed that these inhibitors also block HIV-1
reactivation from latency [14, 17]. Taken together, these
observations demonstrate the importance of the sulfon-
ation pathway at multiple steps of HIV-1 replication. It
will be important for future studies to determine which
sulfotranserase(s) regulate HIV-1 infection and reactiva-
tion from latency in CD4+ T cells, as SULT1A1 does not
appear to be expressed at the protein level in these cells
and control has been demonstrated at level of transcrip-
tion, not reverse transcription, upon treatment with
chlorate and guaiacol.
SULT1A1 is highly polymorphic within the human
population, with both genetic polymorphisms and copy
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Fig. 4 SULT1A1 regulates HIV-1 reverse transcription. a MDMs were treated with control siRNA or SULT1A1-specific siRNA and subesequently challenged
with VSV-G pseudotyped NL43-Luc HIV-1 vector. DNA was isolated 24 h post-infection and qPCR was performed using primers that detect
early RT DNA products or late RT DNA products compared to the cellular PBGD gene as an endogenous control. The levels of early and late
RT products were normalized to the ASN siRNA control. Results shown are from MDMs derived from 6 donors tested twice. b MDMs were
transfected with SULT1A1 siRNA 2 or ASN siRNA and total cellular RNA was isolated 24 h post infection with VSV-G pseudotyped NL43-Luc
HIV-1 vector. qPCR using primers specific for HIV-1 multiply spliced mRNA (MS RNA, forward and reverse primers span the first and second exons of
Tat/Rev, respectively) was performed, and relative MS RNA (normalized to GAPDH) was then normalized to ASN siRNA control. Results shown are from
MDMs derived from 6 donors tested twice. c Representative immunoblot showing HIV-1 Vpu and Vif protein levels compared to endogenous Ku86 or
GAPDH loading control, respectively, from protein lysate collected 48 h post infection with VSV-G pseudotyped NL43-Luc HIV-1 vector pre-treated with
either ASN siRNA control or SULT1A1 siRNA 2. d Quantitative immunoblot analysis using Image Studio software of Vpu and Vif as shown in Fig. 4c.
Mean and SD shown, *** p < 0.0005 ** p < 0.005 * p < 0.05 one sample t test. Results shown are from 6 donors assayed twice. Samples with <60 %
SULT1A1 knockdown and/or <65 % cell viability were not used in the analysis. All values were compared to ASN control
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number variation conferring different levels of enzymatic
activity [46–48]. Moreover, SULT1A1 variation has been
linked to a number of diseases such as cancer [49–52],
heart disease [53], and inflammatory bowel disease [54].
Consequently, we are now seeking to determine if there
is a correlation between SULT1A1 variability and HIV-1
susceptibility and/or AIDS disease progression.
Further investigation will be aimed at determining if
SULT1A1 acts on HIV-1 through a substrate-dependent or
-independent mechanism. It is possible that SULT1A1 may
act independently of substrate by directly modifying viral
proteins (such as reverse transcriptase). If the sulfonation of
a specific SULT1A1 substrate is required, on the other
hand, then identification of that substrate will be critical for
understanding the underlying mechanism involved.
Conclusions
In summary, we demonstrated that a human cytosolic
sulfotransferase, SULT1A1, regulates HIV-1 reverse tran-
scription in human monocyte-derived macrophages
(MDMs). We showed that SULT1A1 is highly expressed
in primary human monocytes and MDMs. RNAi-
knockdown of SULT1A1 in MDMs leads to a substantial
decrease in infection by both pseudotyped and
replication-competent HIV-1 vectors, as well as by a
SIVagm vector. Quantitative PCR analysis revealed that
this effect is associated with a defect in minus-strand
DNA elongation during HIV-1 reverse transcription.
These results support the idea that SULT1A1 is a novel
HIV-1 host factor in MDMs, and suggest that targeting




AllStars Negative control and SULT1A1 Flexitube siR-
NAs (sequences provided in Additional file 2: Table S1)
were obtained from Qiagen, reconstituted at 20 μM in
water, and stored at −20 °C until use. Cell viability was
assayed using Cell Titer-Glo reagent and luciferase activ-
ity was measured using Bright-Glo reagent according to
the manufacturer’s instructions (Promega).
SULT mRNA expression analysis
The expression level for each cytosolic sulfotransferase
in CD4+ T cells and CD14+ monocytes was derived
from publically available expression data from BioGPS
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Fig. 5 SULT1A1 influences the kinetics of minus-strand DNA elongation. a The step during HIV-1 reverse transcription that SULT1A1 regulates was
investigated by quantitative real-time PCR analysis with the indicated primer sets. The stages of reverse transcription are shown: 1. Viral genomic
RNA; 2. Minus-strand DNA initiation; 3. Minus-strand DNA transfer; 4. Minus-strand DNA elongation and plus-strand DNA initiation; 5 and 6. Plus-
strand DNA transfer; 7. Plus-strand DNA elongation. b MDMs were treated with control or SULT1A1-specific siRNA and challenged with VSV-G
pseudotyped NL43-Luc HIV-1 vector. Total cellular DNA was isolated at 8, 16, or 24 h post infection. Quantitative real-time PCR was performed to
measure the relative abundance of DNA products corresponding to specific steps during the process of reverse transcription using primers indicated
in Fig. 5a. Results shown are from MDMs derived from 6 donors assayed once. Mean and SD shown, *** p < 0.0005 ** p < 0.005, one sample t test
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[28], and normalized to the median expression of that
sulfotransferase in all tissues tested.
Peripheral blood mononuclear cells
Human donor buffy coats and LRS-WBC (white blood
cells isolated in the Leuko-Reduction system via Terumo
BCT Trima Automated Collection System) samples were
collected from anonymous healthy donors and obtained
from the San Diego Blood Bank. Written informed con-
sent for the use of buffy coats and LRS samples for re-
search purposes was obtained from the donors by the
San Diego Blood Bank. Samples are routinely tested for
the presence of HIV-1 antibodies and all samples used
in the study are confirmed HIV-1 negative. Peripheral
blood mononuclear cells (PBMCs) were isolated from
these samples by Ficoll density gradient centrifugation.
Briefly, buffy coats and LRS samples were diluted in
RPMI, layered over Ficoll (Ficoll-Paque Plus, GE Health-
care), and centrifuged at 1850 rpm for 25 min without
brakes. Cells at the interface were removed and washed
twice in RPMI. Platelets were then removed by a final
spin at 800 rpm without brakes. The cells were counted
and resuspended at a density of 25x106 cells/ml in FBS
supplemented with 10 % DMSO, transferred to −80 °C
at least overnight, and then to liquid nitrogen for long-
term storage.
CD4+ T cells
PBMCs were thawed in RPMI, washed, and CD4+ T
cells were isolated using CD4+ negative selection mag-
netic bead isolation (EasySep Human CD4+ T cell en-
richment kit, StemCell Technologies). Resting CD4+ T
cells were lysed directly after separation, and the
remaining CD4+ T cells were activated using CD3/CD28
beads for three days (Dynabeads Human T-Activator
CD3/CD28, Life Technologies). CD4+ T cells were re-
suspended at 2x106 cells/100 μl 1× LDS lysis buffer
(Invitrogen), diluted 1:3, and 10 μl lysate was loaded
onto a gel 4–12 % Bis-Tris gel for immunoblot analysis.
Monocyte-derived macrophages
PBMCs were thawed in RPMI, washed, and CD14+
monocytes were isolated using CD14 positive selection
magnetic cell sorting according to the manufacturer’s in-
structions (Easy Sep Human CD14 Positive Selection kit,
StemCell Technologies). CD14+ monocytes were plated
at 5x106 cells per 10 cm polypropylene petri dish
(Fisher) in RPMI 1640 medium (Gibco-BRL) supple-
mented with 10 % Human AB Serum (Sigma), 50 U/ml
penicillin, 50 μg/ml streptomycin, 10 mM HEPES, so-
dium pyruvate, and 20 ng/ml recombinant human M-
CSF (Peprotech). Fresh media without cytokine was
added after 3–4 days, and by day 7 the MDMs were fully
differentiated.
siRNA transfection
MDMs were washed with PBS, treated with Accutase
(Stem Pro Accutase Cell Dissociation Reagent, Life
Technologies) at 37 °C for 30 min, and dissociated by
gentle pipetting. Cells were transfected with siRNA using
the NEON electroporation system (Life Technologies)
according to the manufacturer’s instructions. Briefly,
1.5×105 MDMs were mixed with 3 μl 20 μM siRNA in a
10 μl final reaction volume, electroporated with 2 pulses
of 1500 V for 20 ms, and then transferred to 500 μl pre-
warmed RPMI 10 % human serum without antibiotics in
a 48 well plate and allowed to recover for 4 days. At
4 days post transfection, samples were assayed for pro-
tein knockdown by immunoblot. Samples with <60 %
SULT1A1 knockdown and/or <65 % cell viability were
not used in the analysis.
Viruses and infection
The HIV-1 NL43-Luc and SIVagm plasmids were
obtained from Ned Landau [32, 33]. HIV-1 Env +
JM1186-Rluc plasmid was made by Sumit Chanda’s lab
by cloning the V3 loop of Gp120 from isolate 92TH014
[35] and Renilla luciferase reporter into pBR-NL43-
IRES-eGFP [34]. VSV-G pseudotyped NL43-Luc HIV-1
and Env + JM1186-Rluc HIV-1 viruses were produced by
transient transfection of 293 T cells by the Salk viral vec-
tor core, and VSV-G-pseudotyped SIVagm-Luc was pro-
duced in a similar method as previously described [55].
HIV-1 and SIVagm viruses were assayed for p24 or p27
content, respectively, by p24 or p27 antigen capture
ELISA according to the manufacturer’s instructions
(Zeptometrix).
For MDM infection experiments, media was re-
moved 96 h post transfection with siRNA, replaced
with 100 μl virus (corresponding to 164 ng p24 VSV-G
pseudotyped NL43-Luc HIV-1, 66.3 ng p24 Env +
−JM1186-Rluc HIV-1, 234 ng p27 VSV-G pseudotyped
SIVagm-Luc) diluted in 400 μl fresh RPMI 10 % hu-
man serum, and cells were spinoculated at 1200 × g
for 60 min. Viral reporter expression and cell viability
was assayed 24 h post infection for VSV-G-
pseudotyped viruses, and 3 days post infection for rep-
lication competent HIV-1.
Immunoblot and protein quantitation
Cells were lysed in 1× LDS sample buffer (Invitrogen)
and stored at −20 °C until use. Samples were thawed
on ice, incubated at 95 °C for 5 min, and centrifuged
for 3–5 min before loading. Precision Plus Protein
Dual Color Standards (Bio-Rad) or Novex Sharp Pre-
stained standards (Invitrogen) were used as protein
standards, and 4–12 % Bis-Tris gels (Invitrogen) were
used for gel electrophoresis. Protein was transferred
onto PVDF membrane (Millipore Immobilon-FL)
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using BioRad wet transfer apparatus at 100 V for 1 h
at 4 °C. Membranes were blocked with Casein block-
ing buffer (Bio-Rad) for at least 1 h at room
temperature, then incubated with primary antibody di-
luted in 0.1 % Casein/0.2× PBS + 0.1 % Tween-20 over-
night at 4 °C. Primary antibodies used in the study
include mouse anti-human SULT1A1 mAb (clone
638708, R&D Systems) used at 1:2000 dilution, rabbit
anti-HIV-1 Vif (clone A319, NIH AIDS Reagent pro-
gram) used at 1:500, rabbit anti-HIV-1 Vpu (clone
ab81532, Abcam) used at 1:1000 dilution, mouse anti-
human Ku-86 mAb (clone B-1, Santa Cruz Biotechnol-
ogy) used at 1:500 dilution, and anti-human mouse
GAPDH (clone 6C5, Abcam) used at 1:5000. Mem-
branes were washed three times with 1× PBS/ 0.1 %
Tween-20, incubated with Alexa-Fluor 680-conjugated
secondary antibody diluted in 0.1 % Casein 0.2× PBS
0.1 % Tween-20 and 0.01 % SDS at room temperature
for at least 1 h. Secondary antibodies used in the study
include goat anti-mouse Alexa-Fluor 680 IgG (H + L)
(clone A21057, Invitrogen), and donkey anti-rabbit
Alexa-Fluor 680 IgG (H + L) (clone A10043, Invitro-
gen). Membranes were washed three times with 1×
PBS/ 0.1 % Tween 20, and imaged using the Licor
Odyssey system. Protein expression was quantified
using Image Studio software (Licor).
Detection of nucleic acids by real-time quantitative PCR
Total RNA was prepared using Qiazol lysis reagent (Qia-
gen) and miRNeasy RNA isolation kit (Qiagen) according
to the manufacturer’s instructions. cDNA was synthesized
using Quantitect Reverse Transcription kit (Qiagen) ac-
cording to the manufacturer’s instructions. DNA was iso-
lated from cells using a DNeasy Blood and Tissue Kit
(Qiagen) according to the manufacturer’s instructions.
Quantitation of ERT, LRT, and PBGD was performed
using primers and probes diluted in TaqMan universal
PCR master mix (Invitrogen). Amplification of other DNA
products was monitored using SYBR green fluorescence
(Invitrogen). Real-time PCR was performed using the ViiA
7 Real-time PCR system (Life Technologies). Standard
curves were generated for all primers and efficiencies were
found to be equivalent. Relative expression was calculated
using the delta CT method as previously described [56].
All primer and probe sequences used in the study are in-
cluded in Additional file 2: Table S1.
Additional files
Additional file 1: Figure S1. SULT1A1 is highly expressed in
monocytes. The expression level for each cytosolic sulfotransferase in
CD4+ T cells and CD14+ monocytes was derived from publically
available expression data from BioGPS and normalized to the median
expression of that sulfotransferase in all tissues tested. (PDF 26 kb)
Additional file 2: Table S1. Primer and siRNA sequences. DNA and
RNA primer sequences used in the study are listed from 5′ to 3′. siRNAs
are listed with the siRNA name, Qiagen ID, and sequences from 5′ to 3′.
(XLSX 43 kb)
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